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Abstract
Objectives To explore home medicine practices and safety for people shielding and/or over the age 
of 70 during the COVID-19 pandemic and to create guidance, from the patient/carer perspective, for 
enabling safe medicine practices for this population.
Methods Semi-structured interviews were carried out with 50 UK participants who were shielding 
and/or over the age of 70 and who used medicines for a long-term condition, using telephone 
or video conferencing. Participants were recruited through personal/professional networks and 
through patient/carer organisations. Participants were asked about their experiences of managing 
medicines during the pandemic and how this differed from previous practices. Data were analysed 
using inductive thematic analysis.
Key findings Patients’ and their families’ experiences of managing medicines safely during the 
pandemic varied greatly. Analysis suggests that this was based on the patient’s own agency, the 
functioning of their medicines system pre-pandemic and their relationships with family, friends, 
community networks and pharmacy staff. Medicine safety issues reported included omitted doses 
and less-effective formulations being used. Participants also described experiencing high levels 
of anxiety related to obtaining medicines, monitoring medicines and feeling at risk of contracting 
COVID-19 while accessing healthcare services for medicine-related issues. Effects of the pandemic 
on medicines adherence were reported to be positive by some and negative by others.
Conclusions Pharmacy staff have a key role to play by establishing good relationships with pa-
tients and their families, working with prescribers to ensure medicines systems are as joined up as 
possible, and signposting to community networks that can help with medicines collection.
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Background
Medicines are the most common healthcare intervention. Prior to 
the COVID-19 pandemic, more than 8% of adult emergency hos-
pital admissions and 25% of those for older adults were medication 
related, with increasing age and higher disease burden as key risk 
factors.[1, 2]
During the COVID-19 pandemic, people self-isolating and 
housebound for long periods, due to age or ‘extreme medical vulner-
ability’, were potentially at increased risk of medicine-related prob-
lems. Potential issues included: disrupted routine healthcare services 
and supply chains; altered household mobility, wellbeing and sup-
port structures; restrictions on or reluctance to attending healthcare; 
and misinformation about medicines reported to affect the risk or 
severity of COVID-19 infection. These create additional challenges 
for medicines safety, at a time when prevention of harm is particu-
larly important.
Little is known about changes to household medicines practices 
or safety during a pandemic. Previous studies in pandemics and epi-
demics[3–6] have not considered medicines safety from the viewpoint 
of patients/carers staying at home. In March 2020 in the UK, patients 
classified as ‘extremely clinically vulnerable’ were strongly advised 
by the government to ‘shield’, i.e. not leave their home. Pharmacists 
were paid a fee for home-delivery of medicines to patients on the 
shielding list. Those over 70 could access this service if other med-
ical factors made them extremely clinically vulnerable. Community 
pharmacies experienced some staff shortages during this time where 
staff needed to shield or self-isolate.[7] The objectives of this study 
were to explore home medicines practices and medicines safety for 
people staying at home as much as possible during the COVID-19 
pandemic and to create best practice guidance for medicines man-
agement during a pandemic from the patient/family carer perspec-
tive. The study was carried out in two countries: the UK and Ireland. 
This article presents findings from the UK.
Methods
A qualitative cross-sectional study design was adopted, using semi-
structured interviews. The study was approved by University College 
London Research Ethics Committee (reference: 18417.001) and the 
protocol was published.[8]
Sampling and recruitment
A sample size of 50 was chosen due to anticipated diversity to sup-
port having sufficient information power.[9] Participants were re-
cruited using a combination of convenience and purposive sampling 
to interview a range of participants regarding medical conditions, 
numbers of medicines, ages, genders, living alone versus with others, 
geography and ethnicities.
Adults, living in the UK, were eligible to participate if they met 
the Government’s criteria for shielding during the COVID-19 pan-
demic and/or they were aged 70 years or more and were using at 
least one long-term medicine. Adults assisting in medicines manage-
ment for an adult fulfilling these criteria were also eligible. Those 
under 18 years, unable to consent to interview, or without access to 
telephone or internet were excluded. One participant with limited 
English was included as she had a family member whom she asked 
to assist her during the interview.
Participants were recruited through the researchers’ own personal 
and professional networks, patient and carer charities and organ-
isations, and engagement with our patient and public involvement 
(PPI) partners. Both social media and word-of-mouth were used to 
support recruitment. We kept a matrix of participants’ demographic 
characteristics and medicines to enable us to target later recruitment 
towards less well-represented groups.
Data collection
An interview topic guide was developed, and informed by a priori 
principles of routine lay medicines use[10] (Supplementary Appendix 
1). Informed consent was received from all participants prior to par-
ticipation. Where possible, this was through an electronic signature 
or a signed hard copy of the consent form being posted. Alternatively, 
verbal consent was invited by audio-recorded telephone or video 
call, as approved by the ethics committee.
Interviews were conducted remotely, between June and August 
2020, either by telephone or video conferencing, depending on par-
ticipant preference. Interviews were conducted by two research 
pharmacists working in hospital and academic settings (SG, BDF) 
and a health services researcher (CW). All had previous experi-
ence in conducting qualitative interviews. Interviews were audio-
recorded, transcribed verbatim and anonymised. In two cases where 
the recording failed, detailed notes were made immediately after 
the interview.
Data analysis
A constructivist–interpretive analysis approach was used, with 
the aid of NVivo. A  coding framework was developed iteratively 
by SG, BDF, CW, TG and DK using Safety-I/-II perspectives[11] and 
Schafheutle et al.’s medication work framework[10] as sensitising con-
cepts.[8] A constant comparative technique enabled systematic organ-
isation, comparison and understanding of similarities and differences 
in the data. An iterative approach was taken with analysis being con-
ducted during data collection and emerging themes being explored 
further in remaining interviews. Nine interviews were checked for 
inter-coder reliability among SG, BDF and CW. The remainder of 
the interviews was then coded by SG or CW. Additionally, eight PPI 
representatives open-coded 48 interviews. Each PPI representative 
coded 12 interviews with each interview independently open-coded 
by two PPI representatives. Agreement of emerging themes was 
reached in an online nominal group session. The PPI analysis was 
subsequently integrated with that of the researchers and reviewed by 
all researchers and PPI representatives. All PPI representatives had 
previous training and experience in open coding.
The research was carried out and reported according to Standards 
for Reporting Qualitative Research.[12]
Results
Participants
Fifty people were interviewed (16 males, 34 females; mean age 
68  years, range 26–93  years). Seven identified as being from a 
non-white ethnic group (comprising Caribbean British, Black 
African, Asian British, Asian, Sri Lankan, Indian and Chinese eth-
nicities). Participants were from England, Scotland and Wales, 
with six living in rural areas, one in a semi-rural area, and 43 in 
urban areas. Ten were living alone. Nine reported having a more 
dominant role in helping manage medicines for another adult who 
was over 70 and/or shielding, compared with managing their own 
medicines and focussed on their carer role during the interviews; 
seven of these were female. The number of medicines being taken 
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Diversity of experiences in managing medicines 
during the pandemic
We identified a wide range of experiences. Some participants re-
ported there had been no change – either they already had delivery 
arrangements in place pre-pandemic which continued, or they con-
tinued to collect medicines from a local pharmacy during the pan-
demic. For others, there was a smooth transition from one supply 
system to another, such as a straightforward change to getting medi-
cines delivered or collected by others. For others, there had been an 
initial ‘crisis’ period where obtaining medicines was very difficult at 
the beginning of the pandemic, which had then stabilised.
‘We moved from [pharmacy] which is impossible at the moment, 
you have to queue, etc. to another pharmacy. Obviously, there were 
basic problems at the beginning, not getting things or stuff, but it is 
all working itself out now.’ (participant 32)
For remaining participants, the pandemic served as a ‘tipping 
point’, exacerbating pre-existing challenges.
So [pre-pandemic] when you go to collect […] the things the 
doctor has been prescribing, the other stuff isn’t due for re-
peat, so you are constantly having to go and chase those.’ […] 
‘[Post-pandemic] they would only have half the prescription, 
which they didn’t tell you beforehand, and when we had to 
ask somebody to pick up the prescription and they would then 
come back with the slip saying please collect the other half 
next week […] it meant asking somebody again […] perhaps 
six, seven times in a couple of weeks, You can’t keep asking 
favours all the time, it is quite embarrassing. (participant 22)
Factors affecting the diversity of experiences
Four themes seemed to account for much of this diversity. First, 
many participants described their own proactivity, determination 
and perseverance. Some expressed the view that they were in a more 
privileged position than others due to knowledge of the healthcare 
system, financial resources or ability to self-monitor their conditions.
Second, some participants reported having strong support from 
family, friends and/or community networks that helped them manage 
their medicines, mostly by collecting them.
Third, interview data suggested that support from community 
and hospital pharmacy staff was variable, with some participants 
describing very positive experiences and others negative (Box 1). 
Two key subthemes emerged regarding participants’ experiences of 
Box 1: Participants’ experiences of pharmacy services during the COVID-19 pandemic
Positive experiences
•  ‘Well, I had to have a prescription during the course of the pandemic and so I submitted it in the usual way and they went to the chemist 
and then I actually rang the chemist, because I was in lockdown, and I rang the chemist, and I do actually know them very well and 
they know me very well […] and they kindly said they would deliver it, which they did. It wasn’t very difficult. I think I’m lucky because 
I’ve been going to them for a long time, they’re not far away, I know them and there’s an awful lot in having a personal rapport with 
people when they actually know who they’re speaking to, it’s a great help.’ (participant 35)
•  ‘My local pharmacy have been good that they have been trying to deliver if they could. I don’t know if I’ve been flagged up on their 
system but they phoned me and asked if I wanted it delivered and I said that it was okay, they could deliver to other people [instead] 
that might have needed it before, but they delivered it anyway.’ (participant 33)
•  ‘The Friday morning before the lockdown happened on the Monday, he [pharmacist] rang me and said [name], you are [name of com-
munity organisation] aren’t you … and he said can I have the email addresses of the members so that I can give them, tell them that we 
wanted to do delivery and [I] also explained it’s data protection, we couldn’t give him but he could give me the leaflet [to disseminate] 
if he wanted.’ (participant 23)
•  ‘And finally, two weeks ago, their community pharmacist based at the GP practice who does one day a week in the practice phoned me 
at home and she immediately understood the problem and kind of all the implications that meant for me as a partially sighted person 
who is supposed to be shielding at home, she said don’t worry, I will sort it out and that was great and then the prescription came 
through for all my six meds, so that problem was solved’. (participant 48)
Negative experiences
•  ‘Well, what happened was [name of pharmacy] originally used to[do] a … free delivery, then they installed a payment per person for a 
delivery of £5 and because you know [name of wife] is a person that can’t really go out because of her situation, so we were obliged to 
let them charge but we objected and within a reasonable period of time, they decided in their wisdom that they weren’t going to charge 
and so far they haven’t reintroduced the £5 charge.‘ (participant 44)
•  No, they don’t seem really keen to be delivering to people either, they try and make you…they say is there no friends or anything that 
you could ask?’ (participant 26)
•  ‘Have you got your GP’s letter? Have you got this? You must send somebody round to pick it up. We can’t do this. I said “well, why, 
what’s changed, I’ve had this twice?” You’ve only got to look at the prescription [interviewer name], to see it’s all chest medicine, you 
know, what was the problem? So, anyway, I was getting a bit upset really. It made me feel like a nuisance.’ (participant 43).
•  ‘I went all the way today to pick it up to be told it’s not ready so I really haven’t started taking them yet. […]To be told yes you can 
come in, […] I’m just so furious it wasn’t ready.[…] If the hospital was just down the road I could say I could pick it up but I need a 
bus ride to go.’ (participant 12)
•  ‘Then I came here one day to be told that she’d got a message, or they’d spoken to her, to say that her treatment, her chemo[therapy] 
treatment, was going to stop. So, obviously that caused a bit of distress because we didn’t really understand it but then I was able to 
follow that up and send an email. So I think, again, the fact is I had emails for people I knew and then they got back in touch with 
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pharmacy services: continuity and communication. Some reported 
having used the same local community pharmacy for many years 
with good relationships that continued through the pandemic. 
Others reported having to change from their usual community phar-
macy at the beginning of the pandemic, either due to temporary clos-
ures of services or because the pharmacy was unable to deliver. In 
some cases, delivery services were organised through a separate team 
affiliated with a pharmacy chain and participants, therefore, lost 
continuity with their local provider. Communication between phar-
macy staff and patients/carers, particularly where this was proactive, 
was also identified by participants as being important. However, 
many participants reported a lack of information or receiving misin-
formation. Loss of informal communication channels was reported 
by some as participants were not visiting the community pharmacy 
to collect medicines. Additionally, many reported challenges in con-
tacting pharmacy staff at the beginning of the pandemic when they 
needed to rearrange medicines supplies or monitoring arrangements.
Fourth, the analysis suggested that the pre-pandemic functioning 
of the medicines management system affected its pandemic resili-
ence. The most common issue identified was non-synchronised 
supplies of different medicines, caused by different order dates and 
lengths of supply, resulting in patients/carers having to obtain medi-
cines several times each month. This made obtaining medicines more 
difficult while shielding. Additionally, some patients/carers obtained 
medicines from multiple places, such as from both community and 
hospital pharmacies. Others had different systems for medicines for 
different family members, with some being delivered and others not. 
In addition, when rearranging medicines supplies after the start of 
the pandemic, there was a ‘disconnect’ between prescribed medicines 
and those purchased over-the-counter.
The problem I have got is I don’t get prescribed [loratadine] 
as it is so cheap, I just buy it over-the-counter but as the phar-
macy know I am shielding and everything, they really want it 
on a prescription, so they won’t sell it to me. (participant 27)
In addition to these four main themes, some participants re-
ported roles that doctors had played by issuing prescriptions earlier, 
prescribing medicines that had been purchased over-the-counter pre-
pandemic, or liaising with phlebotomy services to ensure continuity 
of medicines monitoring. Others reported that it was difficult to con-
tact GPs at the start of the pandemic.
Analysis suggested that the above themes were more important 
in accounting for the diversity of experiences described than partici-
pants’ demographic characteristics. However, people of working age 
seemed more likely to report major changes to their routines during 
shielding that affected continuity, for example, if they needed to 
change from collecting their medicines from a pharmacy near work 
to one near home. Taking a large number of medicines did not ne-
cessarily lead to more difficulties if medicines management had been 
working well pre-pandemic. However, having multiple prescribers of 
medicines, e.g. community and hospital, appeared to make changes 
during the pandemic more complex to navigate.
Medicines outcomes related to the pandemic
Some participants described the negative effects of the pandemic 
on their health due to medicines issues experienced. For example, 
some had missed doses of medicines and others had been given less-
effective formulations to avoid needing to use healthcare services.
My medication was way overdue and these are immuno-
suppressants, you can’t suddenly stop taking them, and 
I  hadn’t had any for a couple of months. I  was very achy 
(participant 37).
Even where medicines-related issues did not cause identifiable 
physiological harm, participants described feeling very anxious as a 
result. This is related to obtaining supplies of prescription or over-
the-counter medicines such as paracetamol, getting monitoring tests 
done or concern about catching COVID-19 when accessing pharma-
cies or other healthcare services.
There was a lot of stress getting my medication. I didn’t have 
enough […] but the nurse did say, don’t worry it is not disas-
trous […] if you don’t have quite enough for a week […] but 
it is just a stress and the hassle if I am to get it all sorted out 
(participant 20).
The pandemic appeared to have a range of effects on adherence. 
Some participants reported increasing adherence to ensure their 
long-term conditions were fully under control to help protect them 
against serious COVID-19 infection. Change of routine could have a 
positive or negative effect. Positive effects were reported where par-
ticipants felt they had more time to focus on their medicines because 
they were less busy, and negative effects where medicine-taking was 
integrated into a daily routine that was disrupted.
When I was forgetting to take my medicines before the pan-
demic, it was probably connected to having to rush out, […] 
in the morning, and this […] is kind of not a problem during 
shielding (participant 5).
 I’ve struggled because I’m not going to work, my normal 
routine has been shot so I have regularly forgotten to take 
them in the morning (participant 3).
Negativity linked to the pandemic could also lead to reduced 
adherence. In addition, two participants reported reconsidering 
the risk/benefit ratio of taking the medicines that resulted in them 
needing to shield.
For many participants, all types of medication-related work iden-
tified by Schafheutle et al.[10] changed or increased (Table 1).
Discussion
Patients’ and carers’ experiences of managing medicines safely during 
the pandemic varied enormously, with some participants experien-
cing difficulties, others little change and a small minority experien-
cing some improvements. This variation appeared to be based on 
the patient’s own agency, the functioning of their medicines system 
pre-pandemic, and their relationships with family, friends, commu-
nity networks and pharmacy staff. Medicines safety issues included 
omitted doses and supply of less-effective formulations. There were 
mixed reports of the effects of the pandemic on medicines adher-
ence. Aside from issues related directly to medicines safety, partici-
pants described experiencing high levels of anxiety about obtaining 
medicines, medicines monitoring and feeling at risk of contracting 
COVID-19 while accessing healthcare services to have medicines ad-
ministered or monitored.
To the best of our knowledge, this is the first study to explore 
medicines safety for people who are shielding/over 70 during a pan-
demic from the patient/carer perspective. Our study was enhanced 
by the inclusion of a range of people in data analysis, including PPI 
representatives.
Our recruitment strategy sought to recruit as diverse a range of 
participants as possible and to address safety from both Safety-I and 
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to those experiencing or not experiencing medicines-related issues. 
Nevertheless, our findings suggest that many of our participants had 
a higher-than-average knowledge of the healthcare system. Those 
people we did not reach may have experienced more difficulties with 
their medicines during the pandemic. However, a survey carried out 
with people with disabilities[13] reported those with a higher educa-
tional level experiencing more difficulties with obtaining medicines 
during the pandemic. The reason for this remains unclear. Despite 
our relatively large sample, new themes were constantly emerging 
during data collection and we cannot be sure that our sample size led 
to theoretical saturation.[14] Despite efforts to increase the number of 
male participants, more females than males participated; this may 
be because they were more likely to assist with others’ medicines.[15] 
In addition, these initial results are only from one country and may 
not be generalisable elsewhere. The findings from Ireland, once avail-
able, will shed further light on generalisability.
Laypeople’s anxiety or difficulties about accessing healthcare 
were also reported during the Ebola and H1N1 epi/pandemics,[16–19] 
giving this finding cumulative validity. Recent research investigating 
laypeople’s medication use during the COVID-19 pandemic has fo-
cussed on individual disease states rather than those housebound 
due to (extreme) medical vulnerability.[20–23] These studies considered 
broader aspects of disease management and did not explore lay 
medication-related experiences in-depth. This limits comparison 
with our findings. Nonetheless, variable effects on medication-
adherence,[20, 22–24] challenge accessing healthcare or medication sup-
plies[22–24] and health anxiety[21, 25] were commonly reported. While 
increased self-medication was reported during the Ebola epidemic,[17, 
18] the studies undertaken during COVID-19 did not identify changes 
to self-medication patterns.[20–25] Increased self-alteration of pre-
scribed medication, typically associated with concerns about risk of 
infection or severity of COVID-19 disease,[21–25] has been reported 
previously, consistent with our findings.
Our study findings contribute to the development of both 
the  medication work framework[10] and a Safety-II approach,11 
i.e.  understanding factors that create resilience in medicines sys-
tems. First, there were examples of all areas of medication work 
categorised by Schafheutle et al.10 increasing as a result of the pan-
demic. This suggests that the pandemic added to the illness man-
agement burden and may have made it more difficult to provide 
care that was minimally disruptive to patients’ and carers’ lives.[26] 
We also identified a considerable increase in medicines-related anx-
iety that did not fall under Schafheutle et al.’s[10] initial definition of 
emotional work, suggesting it could be helpful to broaden this def-
inition. Second, in relation to resilience, Fylan et al.[13] identified the 
important role of patients and their families in creating resilience in 
medicines management after hospital discharge. Our study further 
suggests that this role is also important in other situations, such as 
during a pandemic, and that it can be extended to wider commu-
nity networks. As the pandemic was a novel situation, participants 
may have been unable to draw on past experiences. However, they 
drew on anticipatory resilience[27] (proactively making a decision 
or taking a course of action that has an expected consequence in 
a given situation—such as ordering medicines earlier to maintain 
supply) and responsive resilience[27] (reacting effectively when a 
situation changes—such as setting up/accessing community delivery 
services). Vos et  al.[28] identified nurses as an important source of 
medicines resilience; our study suggests that this can be extended 
to pharmacy staff. Our analysis further suggests that continuity and 
communication were two key elements of resilience in medicines 
systems during times of change.
Implications for Practice and Policy
The findings suggest that pharmacy staff can make a significant 
difference during a pandemic, both through proactive, empathic 
Table 1 Changes to the types of medication-related work identified by Schafheutle et al.[10] during the `pandemic
Type of work Example of how affected by the pandemic
Medication–articulation work:  
Activities performed to maintain 
adequate stock and facilitate 
medicine-taking at instructed 
dose time
At the moment, yes my eldest daughter [organises our pill boxes], not the one [other daughter who is shielding] 
who sorts everything [else] out ’. (participant 32)
Surveillance work:  
Monitoring supplies of 
medicines to ensure adequate 
personal stock
‘You have to do [order] it a good 10–12 days before you run out [during the pandemic] so that’s why it’s good 
to have a Dosette [pill] box because you need to make sure [you order it in time], because it can take a time 
to come here and then we are being so careful that if any delivery comes, we are leaving it in our hallway for 
3 days before we open anything.’ (participant 6)
Surveillance–articulation work:  
Surveillance work creating a 
need for participants to act
‘The only way it has changed a bit is that my husband was told to regulate one of the drugs. He was self- 
regulating one of the drugs to deal with a particular problem. […] So, normally he would take this drug every 
week, but he was told to increase it according to his symptoms […]. So, normally, out of the pandemic I wasn’t 
so stressed out about it because he could easily go to the hospital and get guidance whereas at the moment 
you feel if you don’t do as much as possible to keep yourself healthy and well, you know, it could be really 
problematic.’ (participant 47).
Informational work:  
Clarification and checking 
information received from 
other network members and 
resolving medication concerns.
‘The one that I stopped, it was pregabalin, and it was quite a complicated one because you’ve got to wean 
yourself off it slowly and so because I didn’t have access to the [general practitioner’s] surgery or the 
pharmacist really, because I was trying to stay at home, I looked it up on the internet and I did it myself slowly 
[…] I could’ve phoned the pharmacists, I could have phoned or emailed the surgery about it, but I knew that 
they were busy with other things and I thought I could manage that myself.’ (participant 11).
Emotional work:  
Reassurance, reciprocation and 
prompting medicine-taking
‘Because of this [the pandemic], she has lost what I call a keen interest in things […] I have to make sure she 
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communication with patients/carers and by maintaining continuity 
in pharmacy services where possible. Our study did not find ex-
amples of misinformation regarding medicines themselves but did 
reveal examples of misinformation and/or miscommunication about 
services to access medicines, suggesting this as an important area for 
pharmacy staff to focus on.
Pharmacy staff may not be able to meet all patients’/carers’ ex-
pectations regarding delivery, without reimbursement for this service. 
However, a clear explanation and signposting of patients/carers to 
alternative forms of delivery could be a potential solution, in add-
ition to encouraging patients/carers to order medicines earlier than 
usual (see Supplementary Appendix 2 for advice for patients/carers 
co-designed with PPI representatives). Pharmacy staff can also help 
by liaising with GP practices to help ensure patients’ medicines re-
quest dates are synchronised to avoid multiple pickup/delivery each 
month and that prescriptions are issued early enough to allow extra 
time for delivery. Changing to two-monthly prescriptions may also 
be appropriate. These recommendations are also potentially helpful 
for housebound patients beyond the pandemic. We believe that the 
key factors that are important to patients regarding medicines man-
agement are likely to be consistent across countries although systems 
for addressing these may vary.
Conclusions
Our findings suggest considerable diversity in patients’/carers’ ex-
periences of medicines management when staying at home during 
the COVID-19 pandemic, and that this is partly linked to the pro-
vision of pharmacy services. Pharmacy staff can play a key role by 
establishing good relationships, maintaining continuity in service 
provision, working with prescribers to ensure medicines ordering 
dates are as synchronised as far as possible, and facilitating medi-
cines delivery.
Supplementary Material
Supplementary data are available at International Journal of 
Pharmacy Practice online.
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